



(11) (A) No. **1 192 493**

(45) ISSUED 850827

(52) CLASS 167-179
C.R. CL. 167-191

⁴
(51) INT. CL. A61K 31/20, 31/375,
31/585, 31/715

(19) (CA) **CANADIAN PATENT** (12)

(54) Topical Pharmaceutical Compositions

(72) Horrobin, David F.,
Canada
Lieb, Julian,
U.S.A.

(73) Granted to Still Investments Limited
U.S.A.
Lieb, Julian
U.S.A.

(21) APPLICATION No. 420,766

(22) FILED 830202

(30) PRIORITY DATE U.S.A. (345,204) 820203
U.S.A. (458,466) 830117

No. OF CLAIMS 11 - NO DRAWING

Canada

ABSTRACT OF THE DISCLOSURE

TOPICAL PHARMACEUTICAL COMPOSITIONS

- Topical pharmaceutical compositions for the treatment of lesions of the skin or mucous membranes
- 5 containing a physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances
- 10 capable of inhibiting the formation of lipxygenase products, and lysine.

This invention relates to topical pharmaceutical compositions and their use in the treatment of lesions of the skin and mucous membranes.

The oral and parenteral administration of lithium and in particular lithium salts such as lithium carbonate, has found widespread application in the treatment of manic-depressive psychosis. Lithium treatment has been reported as being particularly effective in the treatment of the manic phase of this illness and also in the prophylaxis of both manic and depressive relapses.

It has been reported (Lieb, N.Eng.J.Med. 301(1979), 942) that the oral administration of lithium salts in the treatment of manic-depressive illness has been accompanied by the remission of recurrent herpes infection in a patient additionally suffering from labial herpes and in a patient also having genital herpes.

United States Patent Specification No. 3639625 (issued February 1972 to Sherwin) describes therapeutic compositions containing lithium succinate for treating dermatitis and for producing an antipruritic effect, the compositions thus being suitable for topical application.

Our copending United States Patent Serial No. 4,328,243 filed 7 April 1981, describes a method for the treatment of the side-effects of lithium treatment in a subject suffering from manic-depressive psychosis and undergoing lithium treatment by orally administering to the subject an effective amount of dihomogamma-linolenic acid and/or gamma-linolenic acid or linoleic acid.

We now propose that the conjoint topical administration of lithium with one or more substances selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances
5 capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the in vivo formation of lipoxigenase products, and lysine will be effective in the treatment of lesions of the skin and mucous membranes.

Thus, in one aspect, the invention provides
10 a pharmaceutical composition for topical administration which comprises at least one physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances
15 capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxigenase products, and lysine.

Lesions of the skin and of mucous membranes are generally associated with an inflammatory response,
20 and, in turn, inflammation is believed to be due in part to excessive and/or defective production of certain prostaglandins and related substances. Prostaglandins and related substances are biosynthesised in the body from two main substances, dihomo- γ -linolenic acid
25 and arachidonic acid. In general, prostaglandins of the E-series exhibit a beneficial anti-inflammatory activity, and while minor amounts of such prostaglandins are formed from arachidonic acid, most of the prostaglandin products derived from arachidonic acid show an inflammatory
30 action. The principal prostaglandin product derived from dihomo- γ -linolenic acid is prostaglandin E₁ which exhibits the anti-inflammatory activity. Concomitant with the production of prostaglandins and related substances from dihomo- γ -linolenic acid and arachidonic
35 acid by the cyclo-oxygenase enzyme, other bioproducts are formed from these acids as a result of the action of the enzyme, lipoxigenase. These lipoxigenase products also exhibit an inflammatory action.

Dihomo- γ -linolenic acid and arachidonic acid for metabolism in the body to prostaglandins and lipoxigenase products are usually available either from endogenous stores of these acids or from food sources.

- 5 For example, dihomomath>\gamma-linolenic acid may be biosynthesised from dietary sources of its precursor substances γ -linolenic acid and linoleic acid. In animals arachidonic acid may readily be biosynthesised from dihomomath>\gamma-linolenic acid, but in adult humans such a mechanism is not particularly effective so that the major source of arachidonic acid for prostaglandin synthesis may be from ingestion of the acid per se.

- We now believe that the previously noted activity of lithium succinate for treating dermatitis and for producing an antipuritic effect is due to the ability of lithium to block the release of dihomomath>\gamma-linolenic acid and arachidonic acid from endogenous stores of these compounds, so that the availability of the compounds for conversion to the inflammatory prostaglandins and lipoxigenase products is reduced.

- However, as indicated above, E-series prostaglandins are believed to be beneficial in the treatment of skin and mucous membrane lesions due to their anti-inflammatory activity, so that in one embodiment, the compositions according to the invention incorporate one or more substances which are capable of selectively increasing the in vivo level of E-series prostaglandins.

- For example, the in vivo level of E-series prostaglandins and especially prostaglandin E_1 may be increased by incorporating dihomomath>\gamma-linolenic acid and/or its bioprecursors such as γ -linolenic acid and linoleic acid into the compositions, conveniently in an amount of from 0.01 to 80, preferably from 1 to 15, per cent by weight. If desired, the level of E-series prostaglandins may be increased by including a substance which acts to mobilise the endogenous stores of dihomomath>\gamma-linolenic acid and examples of such substances include physiologically acceptable zinc salts, conveniently

in an amount sufficient to provide from 0.01 to 10, preferably 0.1 to 5 per cent by weight of zinc ions. This object may also be achieved by including in the composition a substances which is capable of activating the bioconversion of dihom- γ -linolenic acid to E-series prostaglandins such as, for example, ascorbic acid (e.g. in an amount of from 0.01 to 20, preferably 0.1 to 5 per cent by weight), ethanol (e.g. in an amount of from 0.01 to 80, preferably 0.1 to 10% per cent, by weight) and spironolactone, (e.g. in an amount of from 0.01 to 20, preferably 0.1 to 5, per cent by weight).

In the body, E-series prostaglandins may themselves act as bioprecursors for other prostaglandins. For example, prostaglandin E_1 may be converted to prostaglandin $Fl\alpha$, which does not show the desired anti-inflammatory action. The level of E-series prostaglandins may therefore be increased by incorporating a substance which is capable of blocking their bioconversion to other prostaglandins. Examples of such substances are rutin and other bioflavanoids. Rutin may conveniently be incorporated into the compositions in an amount of from 0.01 to 20, preferably 0.1 to 10 per cent by weight.

As indicated above, prostaglandins of the E-series form only a minor proportion of the prostaglandin products of the metabolism of arachidonic acid. As the major proportion of the prostaglandin products from arachidonic acid do not provide an anti-inflammatory action, it may therefor be desirable to incorporate into the compositions of the invention a substance which is capable of selectively promoting the formation of E-series prostaglandins in the bioconversion of arachidonic acid. An example of a substance which may be used for this purpose is glutathione, conveniently in an amount of 0.01 to 20, preferably 0.1 to 5, per cent by weight of the composition. It may also be desired to include in the composition a substance which is capable of blocking the conversion of arachidonic

acid to any prostaglandin. On such substance which may be used is (20:5n3) eicosapentaenoic acid and this may conveniently be present in an amount of from 0.01 to 20, preferably 0.1 to 5, per cent by weight.

5 As indicated the biosynthesis of prostaglandins from dihomio- γ -linolenic acid and arachidonic acid by the cyclo-oxygenase enzyme is also associated with the formation of lipoxxygenase products which themselves exhibit inflammatory activity. Thus it has been found
10 that the biosynthesis of the prostaglandins may be inhibited or blocked by substances which are able to inhibit the cyclo-oxygenase enzyme. It has also been found that the formation of lipoxxygenase products may be inhibited or blocked e.g. in the presence of
15 vitamin E and related tocopherols. Thus, in one embodiment, the compositions according to the invention may contain one or more substances which are capable of inhibiting the cyclo-oxygenase enzyme and/or one or more substances which are capable of inhibiting the formation of lip-
20 oxxygenase products optionally in addition to one or more substances which are capable of selectiely increasing the in vivo level of E-series prostaglandins. Substances which are capable of inhibiting the cyclo-oxygenase enzyme include, for example, acetylsalicylic acid,
25 indomethacin, mefenamic acid, ketoprofen, ibuprofen and paracetamol. The formation of lipoxxygenase products may be inhibited by, for example, vitamin E and/or related tocopherols, or any other physiologically acceptable lipoxxygenase inhibitor.

30 Where the compositions according to the invention are to be used for topical application to lesions associated with viral infections, it may be desirable to incorporate lysine, which may be capable of inhibiting viral replication, into the compositions, optionally
35 together with the substance capable of selectively increasing the in vivo level of E-series prostaglandins, the substance capable of inhibiting cyclooxygenase enzyme and/or the substance capable of inhibiting

the formation of lipoxxygenase products. Lysine may conveniently be present in the compositions in an amount of from 0.01 to 20, preferably 0.1 to 5, per cent by weight.

- 5 If oedema is present, this may limit the access of therapeutic agents to cells which are inflamed or infected. It may therefore be advantageous to administer the composition of the invention in a form which is capable of reducing local oedema and which
- 10 will aid the penetration of the other components of the composition to the affected cells. This may be achieved by additionally incorporating one or more high molecular weight polysaccharides into the compositions. Examples of such polysaccharides include dextrans,
- 15 such as dextran sulphate.

- The compositions according to the invention are in a form suitable for topical administration. Examples of such forms include creams, ointments, solutions, suspensions, emulsions, lotions, gels and
- 20 sprays. Such forms may be prepared with pharmaceutical carriers and excipients conventionally used for such purposes. The compositions of the invention are preferably in the form of ointments, which may conveniently be formulated using an appropriate base such as, for example,
- 25 lanolin, paraffin or cetyl alcohol.

- The compositions according to the invention may be used for the treatment of disorders of the skin and mucous membranes e.g. oral, nasal, ocular, aural, genital or gastrointestinal membranes. In
- 30 particular, the compositions may be used in the treatment of pruritis, lesions arising from inflammatory disorders such as eczema and psoriasis and the lesions due to allergic reactions such as to poison ivy as well as having a soothing and analgesic effect on such lesions.
- 35 In addition, the compositions may be used in the treatment of lesions resulting from viral infections, for example the lesions due to infection with herpes viruses such as herpes simplex or herpes zoster, e.g. in herpes

labialis and genitilis, and shingles; as well as lesions arising from superficial wounds, burns, and local poisoning e.g. as a result of insect bites and stings.

Thus, in a further aspect, the invention provides
5 a method for the treatment of lesions of the skin or mucous membranes of a subject, which method comprises topically administering to said lesions an effective amount therefor of a composition according to the invention.

10 The lithium salts employed according to the invention will be physiologically acceptable, and examples of such salts include lithium carbonate, chloride, sulphate, citrate, succinate, salicylate and acetylsalicylate.

15 When the compositions according to the invention contain dihomog γ -linolenic acid this may, if desired, be replaced, at least in part, by an equivalent amount of a biosynthetic precursor thereof such as the above-mentioned γ -linolenic acid or linoleic acid. If desired,
20 these substances may be used in admixture. These substances may also be used in the form of physiologically acceptable functional derivatives thereof such as, for example, their C₁ - C₄ alkyl (e.g. methyl and ethyl) esters and the triglycerides of the acids.
25 Convenient sources of linoleic acid for use according to the invention are the many vegetable oils of which it forms a major constituent. Examples of such oils include cotton-seed, soyabean, peanut, corn, sunflower seed, safflower, poppy seed, linseed and perilla oils,
30 where the linoleic acid occurs in the form of its triglyceride, and the vegetable oils may be used as such i.e. without any treatment to isolate the linoleic acid therefrom.

At the present time known sources of oils having
35 a high γ -linolenic acid content are few. One source currently available is the seed of the Evening Primrose or Oenothera biennis L, the oil extract therefrom containing γ -linolenic acid and linoleic acid in the

form of their triglycerides. Another source of γ -linolenic acid is the seed of Borago officinalis which provides a richer source of γ -linolenic acid with smaller amounts of linoleic acid. Again, these seed
5 oil extracts may be used as such or may, if desired, be fractionated to yield an oil composition enriched in the desired γ -linolenic and/or linoleic acids.

Dihomo- γ -linolenic acid for use according to the invention may be prepared from γ -linolenic acid
10 according to known methods.

If convenient, it may be appropriate to utilise the lithium in the form of a salt with the above mentioned acids, that is with dihomomath>\gamma-linolenic, γ -linolenic or linoleic acid.

15 The bioconversion of linoleic acid to γ -linolenic acid, which is itself subsequently converted to dihomomath>\gamma-linolenic acid, is promoted in the presence of zinc. We have found that the conversion of dihomomath>\gamma-linolenic acid to prostaglandin E₁ is also enhanced by zinc.
20 Thus, as indicated above, the compositions according to the invention may if desired contain a physiologically acceptable zinc salt such as, for example, zinc sulphate or gluconate. The use of a zinc salt in compositions of the invention may be beneficial independent of
25 its effects on fatty acid and prostaglandin metabolism, as it may have healing properties of its own.

Compositions according to the invention conveniently contain an amount of lithium salt sufficient to provide from 0.01 to 25, preferably 1 to 5, per cent by weight
30 of lithium ions in the compositions. When the composition contains vitamin E and/or related tocopherols, these are conveniently present in an amount of 0.01 to 25, preferably 1 to 10, per cent by weight.

Under certain circumstances, it may be desirable
35 to limit the formation of all cyclo-oxygenase and lipooxygenase products from both dihomomath>\gamma-linolenic acid and arachidonic acid. In this situation it may be appropriate to use a combination of a lithium salt

1192493

- 9 -

and a tocopherol which is capable of inhibiting the formation of lipxygenase products without conjointly administering dihom- γ -linolenic acid or its precursors. The following Examples serve to illustrate the invention:

Example 1Ointment

% by weight

	Lithium citrate	8
5	Vitamin E	1
	Oil of Evening Primrose	8
	Zinc sulphate	2
	Dextran sulphate	2

- The above components are formulated with an appropriate ointment base, such as a base containing one or more cetyl alcohols with non-irritant emulsifiers or a lanolin base.

Examples 2-8Ointments

- 15 The following components are formulated in the amounts shown in Table I with an appropriate ointment base, such as those described in Example 1:-

TABLE I

	<u>Ex 2</u>	<u>Ex 3</u>	<u>Ex 4</u>	<u>Ex 5</u>	<u>Ex 6</u>	<u>Ex 7</u>	<u>Ex 8</u>
20	% by weight						
	Lithium succinate	6	8	-	-	-	8
	Lithium citrate	-	-	-	8	8	-
	Lithium acetyl salicylate	-	-	5	-	-	-
25	Vitamin E	1	1	1	1	1	1
	Oil of Evening Primrose	4	-	-	8	5	5
	Zinc sulphate	2	-	-	2	-	-
	Dextran sulphate	2	2	3	-	-	-

30 Examples 9-11Ointments

The following components are formulated in the per

cent by weight amounts shown in Table II with an appropriate ointment base, such as those described in Example

35 1:-

TABLE II

	<u>Ex.9</u>	<u>Ex.10</u>	<u>Ex.11</u>
Lithium succinate	8	-	-
Lithium citrate	-	6	5
Vitamin E	-	1	2
Indomethacin	1	-	2
Mefenamic acid	-	2	-

Examples 12-25

Ointments

The following components are formulated in the per cent by weight amounts shown in Table III with an appropriate ointment base, such as those described in Example 1:-

TABLE III

	<u>Ex. 12</u>	<u>Ex. 13</u>	<u>Ex. 14</u>	<u>Ex. 15</u>	<u>Ex. 16</u>	<u>Ex. 17</u>
Lithium succinate	8	4	-	-	5	-
Lithium citrate	-	-	6	8	-	6
Lithium acetyl- salicylate	-	-	-	-	-	-
Indomethacin	-	0.5	1.0	-	-	-
Vitamin E	1.0	0.5	0.5	1.0	0.5	1.0
Evening primrose oil	2.0	1.0	-	2.0	-	-
Dihomo- γ -linolenic acid	-	-	2.0	-	-	3.0
Zinc sulphate	0.05	0.1	0.2	-	0.05	-
Dextran sulphate	2.0	2.0	3.0	-	-	1.0
Spironolactone	1.0	1.0	0.5	-	0.5	-
Ascorbic Acid	1.0	1.0	2.0	-	-	2.0
Ethanol	5.0	5.0	4.0	-	3.0	-
Eicosapentaenoic acid	1.0	1.0	1.0	-	-	5.0
Glutathione	1.0	1.0	0.5	-	1.0	0.5
Rutin	0.5	1.0	0.5	-	-	-
Lysine	0.5	1.0	2.0	-	-	2.0

TABLE III (cont.)

	<u>Ex. 18</u>	<u>Ex. 19</u>	<u>Ex. 20</u>	<u>Ex. 21</u>	<u>Ex. 22</u>	<u>Ex. 23</u>	<u>Ex. 24</u>	<u>Ex. 25</u>
Lithium succinate	-	-	8.0	-	-	6.0	-	7.0
Lithium citrate	-	-	-	4.0	-	-	5.0	-
Lithium acetyl- salicylate	5.0	10.0	-	-	4.0	-	-	-
Indomethacin	-	-	1.0	-	-	-	-	-
Vitamin E	1.0	1.0	-	-	-	-	-	-
Evening primrose oil	3.0	-	-	2.0	-	-	-	-
Dihomo- γ -linolenic acid	-	-	-	-	-	-	-	-
Zinc sulphate	-	0.5	-	-	-	-	-	-
Dextran sulphate	-	-	-	-	-	-	-	-
Spironolactone	-	-	-	-	-	1.0	-	-
Ascorbic Acid	-	1.0	-	-	-	-	-	-
Ethanol	5.0	-	-	-	-	-	-	-
Eicosapentaenoic acid	-	-	-	-	2.0	-	-	-
Glutathione	1.0	2.0	-	-	-	-	-	2.0
Rutin	0.5	-	-	-	-	-	-	-
Lysine	1.0	0.5	-	-	-	-	1.0	-

CLAIMS

1. A pharmaceutical composition for topical administration which comprises at least one physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxigenase products, and lysine.
2. A composition according to claim 1 wherein the substance capable of selectively increasing the in vivo level of E-series prostaglandins is selected from dihomio- γ -linolenic acid and bioprecursors therefor, substances capable of mobilising endogenous dihomio- γ -linolenic acid, substances capable of activating the bioconversion of dihomio- γ -linolenic acid to E-series prostaglandins, substances capable of blocking the bioconversion of E-series prostaglandins to other prostaglandins, substances capable of promoting the bioconversion of arachidonic acid to E-series prostaglandins and substances capable of blocking the bioconversion of arachidonic acid to prostaglandins.
3. A composition according to claim 2 wherein the substance capable of selectively increasing the in vivo level of E-series prostaglandins is dihomio- γ -linolenic acid, γ -linolenic acid or linoleic acid.
4. A composition according to claim 2 wherein the substance capable of mobilising endogenous dihomio- γ -linolenic acid is a physiologically acceptable zinc salt.
5. A composition according to claim 2 wherein the substance capable of activating the bioconversion of dihomio- γ -linolenic acid to E-series prostaglandins is ascorbic acid, ethanol or spironolactone.

6. A composition according to claim 2 wherein the substance capable of blocking the bioconversion of E-series prostaglandins to other prostaglandins is rutin.
7. A composition according to claim 2 wherein the substance capable of promoting the bioconversion of arachidionic acid to E-series prostaglandins is glutathione.
8. A composition according to claim 2 wherein the substance capable of blocking the bioconversion of arachidonic acid to prostaglandins is (20:5n3) eicosapentaenoic acid.
9. A composition according to claim 1 wherein the substance capable of inhibiting cyclooxygenase enzyme is selected from acetylsalicylic acid, indomethacin, mefenamic acid, ketoprofen, ibuprofen and paracetamol.
10. A composition according to claim 1 wherein the substance capable of inhibiting the in vivo formation of lipoxigenase products is selected from vitamin E and related tocopherols.
11. A composition according to claim 1 which additionally contains a dextran.

FETHERSTONHAUGH & CO.
OTTAWA, CANADA

PATENT AGENTS

